Topics

Pharmaceutical Industry
MannKind shares rise 10% after insulin drug Afrezza OKd by FDA
MannKind shares rise 10% after insulin drug Afrezza OKd by FDA

MannKind Corp., the Valencia company that last week won approval to market an inhalable form of insulin to people with diabetes, saw its shares climb 10% on Monday. The Food and Drug Administration announced Friday that it had approved MannKind's drug, called Afrezza, after more than a decade of research, trials and setbacks for the company. MannKind shares closed Monday at $10.96, up 96 cents. The FDA approved Afrezza for use by people with Type 1 and Type 2 diabetes. But the agency said it would require MannKind to include a warning on the label that it should not be used by people with asthma or chronic obstructive pulmonary disease. Afrezza is a powder insulin that is...

Loading